Highbridge Capital Management LLC grew its position in NxStage Medical, Inc. (NASDAQ:NXTM) by 75.6% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 70,255 shares of the medical device company’s stock after purchasing an additional 30,255 shares during the quarter. Highbridge Capital Management LLC owned approximately 0.11% of NxStage Medical worth $1,959,000 as of its most recent filing with the SEC.
Other large investors have also recently bought and sold shares of the company. NumerixS Investment Technologies Inc bought a new stake in shares of NxStage Medical in the 2nd quarter valued at $122,000. Tower Research Capital LLC TRC bought a new stake in shares of NxStage Medical in the 3rd quarter valued at $136,000. Keybank National Association OH bought a new stake in shares of NxStage Medical in the 2nd quarter valued at $212,000. Quantitative Systematic Strategies LLC bought a new stake in shares of NxStage Medical in the 2nd quarter valued at $216,000. Finally, Janus Henderson Group PLC bought a new stake in shares of NxStage Medical in the 2nd quarter valued at $234,000. 83.58% of the stock is currently owned by institutional investors.
A number of equities research analysts have recently commented on the stock. BidaskClub lowered shares of NxStage Medical from a “buy” rating to a “hold” rating in a research note on Wednesday, November 28th. Zacks Investment Research raised shares of NxStage Medical from a “sell” rating to a “hold” rating in a research note on Wednesday, October 10th. Finally, ValuEngine raised shares of NxStage Medical from a “hold” rating to a “buy” rating in a research note on Friday, October 12th.
Shares of NASDAQ NXTM opened at $28.86 on Friday. NxStage Medical, Inc. has a 12-month low of $22.70 and a 12-month high of $29.26.
NxStage Medical (NASDAQ:NXTM) last issued its earnings results on Wednesday, November 7th. The medical device company reported $0.01 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.02) by $0.03. The business had revenue of $108.12 million for the quarter, compared to analyst estimates of $108.07 million. NxStage Medical had a negative net margin of 1.29% and a negative return on equity of 2.50%. Sell-side analysts expect that NxStage Medical, Inc. will post -0.02 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: This story was first published by American Banking News and is owned by of American Banking News. If you are reading this story on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this story can be viewed at https://www.americanbankingnews.com/2018/12/08/highbridge-capital-management-llc-has-1-96-million-stake-in-nxstage-medical-inc-nxtm.html.
About NxStage Medical
NxStage Medical, Inc, a medical technology company, develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure. Its primary product includes the System One, a portable hemodialysis system, which is used primarily for home hemodialysis and a range of dialysis therapies to deliver in the home setting.
Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.